This is a routine refinancing that extends debt maturity by 5 years and maintains the same $1.8B commitment size. No financial data or guidance was reported. The covenant package is standard and the step-up for qualifying acquisitions signals flexibility for dealmaking. Monitor for any material acquisition announcements that could utilize the accordion feature or trigger the higher leverage limits.
Price Chart
Executive Summary
Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit agreement. The facility matures on May 22, 2031, and carries financial covenants including a maximum consolidated leverage ratio of 4.00x (stepping to 4.50x post-qualifying acquisition), a maximum portfolio cash flow ratio of 5.00x, and a minimum coverage ratio of 2.50x. This refinancing extends Royalty Pharma's debt maturity profile and maintains ample liquidity for acquisitions and working capital.
Key Financial Metrics
Key Facts
- Royalty Pharma entered a $1.8B unsecured revolving credit facility on May 22, 2026.
- The facility matures on May 22, 2031 (5-year term).
- The agreement refinanced and replaced the prior $1.8B facility from September 2021.
- Financial covenants include: max consolidated leverage ratio 4.00x (4.50x step-up for qualifying acquisitions), max portfolio cash flow ratio 5.00x (5.50x step-up), min coverage ratio 2.50x.
- Initial pricing is at Level 2 (BBB/BBB/Baa2) with an applicable margin of 1.125% over Term SOFR and an unused commitment fee of 0.10%.
- The facility includes an accordion feature allowing up to $900M in additional commitments.
- L/C sublimit is $100M.
- Proceeds can be used for working capital, acquisitions, and purchase of royalty assets.
Financial Impact
Refinancing of $1.8B revolving credit facility with a 5-year maturity, same size as prior facility. No new net debt created.
Risk Factors
- Leverage could increase if the company funds large acquisitions, though the step-up covenants provide buffer.
- Uncertainty around future interest rates could impact borrowing costs on drawn amounts.
- No financial performance data was provided in this filing to assess current credit metrics.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-245163 |
| Document: d131735d8k.htm | 0001193125-26-245163 |
| Document: 0001193125-26-245163-index-headers.html | 0001193125-26-245163 |
| Document: 0001193125-26-245163-index.html | 0001193125-26-245163 |
| Document: 0001193125-26-245163.txt | 0001193125-26-245163 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Press Release | $60.59 $58.47 | ▲ +3.50% | ▲ +2.38% | $57.16 (+5.66%) |
Aug 19, 2026 6w ago | Insider Cluster | $61.73 $61.80 | ▲ +0.11% | ▲ +0.50% | $57.16 (−7.40%) |
Aug 12, 2026 7w ago | 144 | $58.56 $60.58 | ▲ +3.45% | ▲ +5.41% | $57.16 (−2.39%) |
Aug 5, 2026 8w ago | 8-K | $57.75 $59.22 | ▲ +2.55% | ▲ +2.19% | $57.16 (−1.02%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
May 28, 2026 18w ago | Insider Cluster | $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $57.16 (+2.51%) |
May 28, 2026 18w ago | 8-K | $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $57.16 (+2.51%) |
May 22, 2026 19w ago | Insider Cluster | $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $57.16 (+4.88%) |
May 15, 2026 19w ago | Insider Cluster | $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $57.16 (+9.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access